Saudi Pharmacopoeia Launched By SFDA CEO Dr. Hisham Aljadhey At Global Health Exhibition

The Saudi Food and Drug Authority (SFDA) has introduced the "Saudi Pharmacopoeia" during the Global Health Exhibition in Riyadh. Dr. Hisham Aljadhey, CEO of SFDA, highlighted this as a significant step for Saudi Arabia in the pharmaceutical sector. The event took place at the Riyadh Exhibition and Convention Center in Malham from October 27 to 30, under the theme "Invest in Health."

The Saudi Pharmacopoeia is designed to enhance the compliance of pharmaceutical products with top-tier quality, efficacy, and safety standards. It includes unique chapters like the "Halal" chapter, setting a regulatory precedent among global pharmacopoeias. This initiative aligns with Islamic Sharia standards, boosting confidence in regional and international markets.

Dr. Aljadhey stated that the SFDA is spearheading this national project to advance the drug regulatory system. This effort reflects Saudi Arabia's prominent position in medicine globally. The Pharmacopoeia supports national pharmaceutical industry growth and aligns with international regulations while considering local needs.

The Saudi Pharmacopoeia aims to increase competitiveness among local manufacturers and attract foreign investment into the Saudi market. It establishes clear quality and testing requirements, facilitating regulatory compliance and supporting localization programs. This initiative also focuses on building human capacity and increasing consumer trust in marketed products.

The Pharmacopoeia serves as an official reference for determining quality specifications for medicines and vaccines, including formulation and analysis methods. It provides a scientific foundation used by regulatory bodies, pharmaceutical companies, and laboratories to ensure drug safety and quality. Additionally, it contributes to research growth and innovation within the sector.

The Global Health Forum acts as a key platform for healthcare innovation, gathering leading figures in the health sector. Its goal is to improve healthcare systems worldwide by fostering innovative solutions that positively impact global health systems.

This initiative aligns with the objectives of the Health Sector Transformation Program under Saudi Vision 2030. By enhancing local pharmaceutical competitiveness on a global scale, it supports broader economic goals while ensuring high standards of health care within the Kingdom.

With inputs from SPA